title: Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
abstract: BACKGROUND
  In recent years platinum-based chemotherapy has become the standard of care for patients with good performance status after complete resection in stages IB-IIIA non-small-cell lung cancer (NSCLC), although the benefit is mainly in stages II and IIIA.
  
  
  METHODS
  In a retrospective trial we evaluate the clinical efficacy and toxicity profile of a platinum- and taxanes-based adjuvant chemotherapy in completely resected IB-IIIA NSCLC. The primary end point was relapse- free survival (RFS); principal secondary end points were overall survival (OS) and safety of the regimen. Potential predictive factors of efficacy and clinical patterns of relapse were also analysed.
  
  
  RESULTS
  From January 2003 to December 2006, 41 patients met the inclusion criteria and were evaluable. Median age at diagnosis was 68.1 years (CI 95% 54-72; range 45-78). Most patients were males (87.7%) and had an Eastern Cooperative Oncology Group performance status score (PS) of 0-1 (87.8%), and 53.6% had adenocarcinomas. Pathological stages were as follow: 48.7% stage IB, 24.3% stage II and 26.8% stage IIIA. 75.6% of patients underwent a lobectomy and mediastinal lymphadenectomy and were treated with a combination of carboplatin AUC6 and paclitaxel 200 mg/m2 (85.36%) for 3 or 4 cycles. With a median follow-up of 18.2 months (range 5.1-46.5), 26 patients (63%) were free of disease and 32 of them were alive (78%). Median RFS was 12.1 months (CI 95% 9.8-14.9) and median OS had not been reached at the time of analysis. Patients with PS< or =1 at diagnosis had a higher RFS [p=0.051 (CI 95% 0.90-0.96)]. Toxicity was generally mild and haematologic events were the most frequent. Non-haematologic toxic effects of chemotherapy were asthenia/ anorexia (12.2%), nausea/vomiting (12.2%) and peripheral neuropathy (17%), but severe toxic effects (grade 3 or greater) were uncommon (<10%). We did not observe treatment-related deaths.
  
  
  CONCLUSIONS
  Platinum-taxane-based adjuvant chemotherapy in IB-IIIA NSCLC following complete resection is feasible, well tolerated and can be delivered in most patients in the adjuvant setting. Ongoing molecular studies may have value in determining which patients will benefit from adjuvant chemotherapy.
authors.affiliation: Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain. anabelencustodio@hotmail.com
authors.forename: Ana Belén
authors.initials: AB
authors.lastname: Custodio Carretero
authors.forename: José Angel
authors.initials: JA
authors.lastname: García Sáenz
authors.forename: José Luis
authors.initials: JL
authors.lastname: González Larriba
authors.forename: Jana
authors.initials: J
authors.lastname: Bobokova
authors.forename: Antonio
authors.initials: A
authors.lastname: Calles Blanco
authors.forename: Florentino
authors.initials: F
authors.lastname: Hernando Trancho
authors.forename: Beatriz
authors.initials: B
authors.lastname: García Paredes
authors.forename: Laura
authors.initials: L
authors.lastname: Rodríguez Lajusticia
authors.forename: Eduardo
authors.initials: E
authors.lastname: Díaz-Rubio García
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin
references.citation: J Clin Oncol. 2005 Aug 1;23(22):4999-5006
references.pmid: 16051951
references.citation: Cancer. 1999 Nov 1;86(9):1867-76
references.pmid: 10547562
references.citation: Clin Cancer Res. 2002 Jul;8(7):2286-91
references.pmid: 12114432
references.citation: J Clin Oncol. 2005 May 20;23(15):3480-7
references.pmid: 15908657
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5506-18
references.pmid: 17954710
references.citation: Lancet. 1992 Jan 4;339(8784):1-15
references.pmid: 1345950
references.citation: J Clin Oncol. 2004 May 15;22(10):1878-85
references.pmid: 15143080
references.citation: Chest. 2000 Feb;117(2):374-9
references.pmid: 10669677
references.citation: N Engl J Med. 2007 Feb 22;356(8):800-8
references.pmid: 17314339
references.citation: Radiother Oncol. 2002 Jan;62(1):11-9
references.pmid: 11830308
references.citation: N Engl J Med. 2004 Jan 22;350(4):351-60
references.pmid: 14736927
references.citation: J Thorac Cardiovasc Surg. 1987 Sep;94(3):349-54
references.pmid: 3041124
references.citation: Cancer. 2001 Oct 15;92(8):2142-7
references.pmid: 11596031
references.citation: N Engl J Med. 2005 Jun 23;352(25):2589-97
references.pmid: 15972865
references.citation: Cancer Chemother Pharmacol. 2007 Sep;60(4):495-501
references.pmid: 17143600
references.citation: J Clin Oncol. 1996 Apr;14(4):1048-54
references.pmid: 8648356
references.citation: N Engl J Med. 2006 Aug 10;355(6):570-80
references.pmid: 16899777
references.citation: N Engl J Med. 2000 Oct 26;343(17):1217-22
references.pmid: 11071672
references.citation: J Thorac Oncol. 2007 Apr;2(4):287-92
references.pmid: 17409799
references.citation: Thorax. 2006 Jul;61(7):597-603
references.pmid: 16449262
references.citation: Br J Cancer. 1996 Aug;74(4):632-9
references.pmid: 8761382
references.citation: Lung Cancer. 2003 May;40(2):181-6
references.pmid: 12711119
references.citation: Chest. 1995 Jul;108(1):246-54
references.pmid: 7606966
references.citation: J Natl Cancer Inst. 2003 Jan 15;95(2):105-12
references.pmid: 12529343
references.citation: N Engl J Med. 2006 Sep 7;355(10):983-91
references.pmid: 16957145
references.citation: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004699
references.pmid: 15674959
references.citation: Eur Respir J. 2001 Dec;18(6):1059-68
references.pmid: 11829087
references.citation: Ann Oncol. 2005 Jan;16(1):75-80
references.pmid: 15598942
references.citation: J Clin Oncol. 2005 Jan 1;23(1):175-83
references.pmid: 15625371
references.citation: Chest. 1997 Jun;111(6):1710-7
references.pmid: 9187198
references.citation: Cancer. 1999 Jul 15;86(2):265-73
references.pmid: 10421262
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):925-9
references.pmid: 10863061
references.citation: Lancet. 1998 Jul 25;352(9124):257-63
references.pmid: 9690404
references.citation: BMC Cancer. 2007 May 08;7:77
references.pmid: 17488518
references.citation: J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61
references.pmid: 14519751
references.citation: Int J Cancer. 1993 Dec 2;55(6):891-903
references.pmid: 8253525
references.citation: J Thorac Oncol. 2007 Jul;2(7):638-44
references.pmid: 17607120
references.citation: N Engl J Med. 2007 Jan 4;356(1):11-20
references.pmid: 17202451
references.citation: BMJ. 1995 Oct 7;311(7010):899-909
references.pmid: 7580546
references.citation: Lancet Oncol. 2006 Sep;7(9):719-27
references.pmid: 16945766
references.citation: N Engl J Med. 2004 Apr 22;350(17):1713-21
references.pmid: 15102997
references.citation: Br J Cancer. 2006 Oct 9;95(7):817-21
references.pmid: 16969350
references.citation: Int J Mol Med. 2004 Dec;14(6):959-70
references.pmid: 15547660
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: Eur J Cardiothorac Surg. 2004 Jul;26(1):173-82
references.pmid: 15200998
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: Ann Thorac Surg. 1984 Oct;38(4):331-8
references.pmid: 6091575